New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 23, 2014
10:02 EDTSFBS, TIF, REN, RYAM, PEGI, MOV, LDRH, KW, ENBL, EOX, DMND, A, NILE, ACTOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Actavis (ACT) resumed with an Overweight at JPMorgan... Agilent (A) reinstated with a Neutral at Goldman... Blue Nile (NILE) initiated with a Market Perform at Barrington... Diamond Foods (DMND) initiated with an Outperform at Credit Suisse... Emerald Oil (EOX) initiated with a Buy at Brean Capital... Enable Midstream (ENBL) initiated with a Market Perform at Wells Fargo... Kennedy Wilson (KW) initiated with a Buy at Deutsche Bank... LDR Holding (LDRH) initiated with an Outperform at RBC Capital... Movado (MOV) initiated with an Outperform at Barrington... Pattern Energy (PEGI) initiated with a Buy at KeyBanc... Rayonier Advanced Materials (RYAM) initiated with an Outperform at RBC Capital... Resolute Energy (REN) initiated with a Neutral at Global Hunter... ServisFirst (SFBS) initiated with an Outperform at Raymond James... Tiffany (TIF) initiated with a Market Perform at Barrington.
News For ACT;NILE;A;DMND;EOX;ENBL;KW;LDRH;MOV;PEGI;RYAM;REN;TIF;SFBS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 17, 2014
10:00 EDTTIFOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:47 EDTACTValeant will not raise Allergan bid ahead of record date, CNBC reports
Valeant (VRX) will not raise its hostile takeover bid for Allergan (AGN) ahead of the record date for the vote, CNBC's David Faber reports. Allergan (AGN) is not currently in takeover talks with Actavis (ACT), Faber added.
09:45 EDTACTAllergan not in deal talks with Actavis, CNBC reports
05:32 EDTTIFTiffany initiated with an Equal Weight at Barclays
Subscribe for More Information
October 16, 2014
17:27 EDTACTNoven files patent infringement suit against Actavis
Subscribe for More Information
15:10 EDTACTAmerican College of Gastroenterology to hold annual meeting
ACG Annual Scientific Meeting 2014 to be held in Philadlephia, PA on October 17-22.
10:01 EDTTIFOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:08 EDTACTActavis confirms generic Quillivant XR patent challenge
Subscribe for More Information
08:02 EDTACTIronwood announces initiation of Phase II linaclotide trial
Ironwood Pharmaceuticals (IRWD) announced the initiation of a Phase II clinical trial evaluating linaclotide for the treatment of adults suffering from opioid-induced constipation. Data are expected in the second half of 2015. The clinical trial is being conducted jointly by Ironwood and Actavis plc (ACT), Ironwood’s co-development and co-promotion partner for linaclotide in the United States. Linaclotide is a guanylate cyclase-C agonist approved by the FDA for the treatment of adults with irritable bowel syndrome with constipation or chronic idiopathic constipation. Linaclotide is not currently approved for the treatment of OIC. The randomized, double-blind, placebo-controlled, multi-site Phase II clinical trial is expected to enroll approximately 240 adult patients with chronic, non-cancer pain who have been receiving a stable dose of an opioid analgesic and suffer from constipation, defined as fewer than three spontaneous bowel movements per week. Patients will be randomized to receive 145 mcg of linaclotide, 290 mcg of linaclotide, or placebo for eight weeks. The primary endpoint of the trial is an increase in SBM frequency. Additionally, a number of secondary endpoints and exploratory analyses intended to inform future development plans are included in the study design.
05:36 EDTTIFTiffany upgraded to Outperform from Neutral at Macquarie
Subscribe for More Information
October 15, 2014
07:43 EDTKWKennedy Wilson has reached attractive entry point, says JMP Securities
Subscribe for More Information
07:25 EDTEOXCanaccord to hold a conference
Subscribe for More Information
October 14, 2014
13:05 EDTAAgilent sees FY15 revenue declining $20M-$30M due to NMR business closure
Subscribe for More Information
13:03 EDTAAgilent sees Q4 EPS 87c-91c, consenssus 89c
Subscribe for More Information
13:02 EDTAAgilent to close Nuclear Magnetic Resonance business
Subscribe for More Information
07:46 EDTACTActavis should be able to mitigate Irish tax downside, says Leerink
Subscribe for More Information
06:03 EDTACTMarket overreacted to new Irish tax rules, says BMO Capital
BMO Capital believes the market may have overreacted yesterday to the report that Ireland is eliminating the "Double Irish" tax loophole. The firm says Allergan (AGN) confirmed that it incorporated potential changes to Irish tax law in its recently raised earnings guidance while Mallinckrodt (MNK) said it does expect the new tax structure to have an immediate impact. BMO views yesterday's pullback in shares of Allergan, Mallinckrodt and Actavis (ACT) as an overreaction.
October 13, 2014
15:12 EDTACTActavis may see modest negative impact from Irish tax change, says BMO Capital
Subscribe for More Information
13:51 EDTKWKennedy Wilson management to meet with JMP Securities
Subscribe for More Information
13:19 EDTLDRHLDR Holding management to meet with JMP Securities
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use